Treatment of mild to moderate infections caused by susceptible strains of designated microorganisms: Pharyngitis/tonsilitis caused by Streptococcus pyogenes; acute bacterial otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains) or Streptococcus pyogenes; acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-β-lactamase-producing strains only); acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (β-lactamase negative strains) or Haemophilus parainfluenzae (β-lactamase negative strains); uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including β-lactamase-producing strains) or Streptococcus pyogenes; uncomplicated urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae; uncomplicated gonorrhea, urethral and endocervical, caused by penicillinase- and nonpenicillinase-producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal in females, caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae; and early Lyme disease (erythema migrans) caused by Borrelia burgdorferi.
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
